- Home
- CLRB vs SYBX Comparison
CLRB vs SYBX Comparison
Compare CLRB & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- SYBX
- Stock Information
- Founded
- CLRB 2002
- SYBX N/A
- Country
- CLRB United States
- SYBX United States
- Employees
- CLRB N/A
- SYBX N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- CLRB Health Care
- SYBX Health Care
- Exchange
- CLRB Nasdaq
- SYBX Nasdaq
- Market Cap
- CLRB 12.5M
- SYBX 13.6M
- IPO Year
- CLRB N/A
- SYBX N/A
- Fundamental
- Price
- CLRB $0.25
- SYBX $1.13
- Analyst Decision
- CLRB Hold
- SYBX
- Analyst Count
- CLRB 2
- SYBX 0
- Target Price
- CLRB N/A
- SYBX N/A
- AVG Volume (30 Days)
- CLRB 728.8K
- SYBX 11.5K
- Earning Date
- CLRB 05-13-2025
- SYBX 05-20-2025
- Dividend Yield
- CLRB N/A
- SYBX N/A
- EPS Growth
- CLRB N/A
- SYBX N/A
- EPS
- CLRB N/A
- SYBX 0.21
- Revenue
- CLRB N/A
- SYBX N/A
- Revenue This Year
- CLRB N/A
- SYBX N/A
- Revenue Next Year
- CLRB N/A
- SYBX N/A
- P/E Ratio
- CLRB N/A
- SYBX $5.30
- Revenue Growth
- CLRB N/A
- SYBX N/A
- 52 Week Low
- CLRB $0.22
- SYBX $0.90
- 52 Week High
- CLRB $3.49
- SYBX $1.91
- Technical
- Relative Strength Index (RSI)
- CLRB 39.17
- SYBX 45.73
- Support Level
- CLRB $0.23
- SYBX $1.00
- Resistance Level
- CLRB $0.27
- SYBX $1.19
- Average True Range (ATR)
- CLRB 0.02
- SYBX 0.09
- MACD
- CLRB -0.00
- SYBX 0.00
- Stochastic Oscillator
- CLRB 15.12
- SYBX 55.00
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.